Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

549.16
+16.383.07%
Post-market: 549.160.00000.00%19:30 EDT
Volume:577.86K
Turnover:315.99M
Market Cap:23.55B
PE:19.65
High:551.15
Open:528.92
Low:528.92
Close:532.78
52wk High:609.35
52wk Low:409.07
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.52
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.68
PE(LYR):19.71

Loading ...

Liquidia says court ruled two of six ‘327 patent claims infringed by company

TIPRANKS
·
Oct 01

Liquidia Corporation - Uthr Requests Injunctive Relief to Restrict Yutrepia Market Availability

THOMSON REUTERS
·
Oct 01

Liquidia Corporation: "Respectfully Disagree with Court's Decision Regarding Claims 1 and 14"

THOMSON REUTERS
·
Oct 01

Liquidia Corporation - Parties to Submit Form of Judgment Specifying Remedy Within One Week

THOMSON REUTERS
·
Oct 01

Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist

TIPRANKS
·
Oct 01

United Therapeutics Gets Legal Win in Patent Litigation Against Liquidia

Dow Jones
·
Oct 01

United Therapeutics Shares up 12.2% After Co Wins Court Ruling Against Liquidia

THOMSON REUTERS
·
Oct 01

Judge upholds claims 1, 14 of United Therapeutics’ ‘327 patent

TIPRANKS
·
Oct 01

United Therapeutics Corp Stock (UTHR) Moved Up by 12.20% on Sep 30: Key Drivers Unveiled

TradingKey
·
Oct 01

United Therapeutics up 13% to $543.85 following Liquidia patent ruling

TIPRANKS
·
Oct 01

United Therapeutics rises 13.2%

TIPRANKS
·
Oct 01

Movement Alert|United Therapeutics Rises 11.53% in Regular Trading, Multiple Catalysts Including FDA Filings and Share Buyback Drive Largest Gain Since March

Market Focus
·
Sep 30

United Therapeutics Chairperson, CEO Martine Rothblatt Reports UTHR Common Share Disposal Worth $4.61 Million

Reuters
·
Sep 29

United Therapeutics Downgraded to Sell as Premium Valuation Clashes with Shrinking Core Business and Challenging Launch Outlook for Tyvaso and Jenraldi

TIPRANKS
·
Sep 25

United Therapeutics Chairperson, CEO Martine A. Rothblatt Reports Disposal of Common Shares Worth $4.4 Million

Reuters
·
Sep 25

United Therapeutics initiated with a Sell at Goldman Sachs

TIPRANKS
·
Sep 24

United Therapeutics Chairperson and CEO Martine A. Rothblatt Disposes of 9,500 Common Shares Worth $4.69 Million

Reuters
·
Sep 23

United Therapeutics EVP, General Counsel Paul A. Mahon Disposes of USD 4.12 Million in Common Shares

Reuters
·
Sep 19

United Therapeutics CEO Martine A. Rothblatt Disposes of 9,500 Shares Worth USD 4.76 Million

Reuters
·
Sep 17

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Reuters
·
Sep 14